DUOFAG
AXP000234.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- MB Pharma
- Sponsor
- MB Pharma
Names
| Name | Type | Source |
|---|---|---|
| DUOFAG | preferred name, brand | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- bacteriophage cocktail against S. aureus and P. aeruginosa
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06319235 | Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® | Unknown | Phase 1/2 | 2023-10-27 | 2025-12-31 | 52 | Bacterial Infections; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Surgical Site Infection; Surgical Wound Infection |
Recent changes
No changes recorded in its trials yet.
Notes
Phage preparation against Staphylococcus aureus and Pseudomonas aeruginosa for infected surgical wounds; phase 1/2a NCT06319235.
How to cite
DUOFAG (AXP000234.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000234.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.